Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

15.05 +0.37 (+2.52%)
Streaming Delayed Price Updated: 10:56 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts ↗
 
Via Benzinga
News headline image
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations For 4D Molecular Therapeutics's Future ↗
 
Via Benzinga
News headline image
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements. 
Via Benzinga
News headline image
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.